Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 13/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14059631 | 0.86 | PDE10A (0.52) | FFAR1PDE10A | |
| SCHEMBL901669 | 0.86 | PDE10A (0.52) | FFAR1PDE10A | |
| SCHEMBL20198842 | 0.84 | PDE10A (0.45) | FFAR1MAPTRAB9APDE10A | |
| SCHEMBL20198858 | 0.84 | PDE10A (0.45) | FFAR1MAPTRAB9APDE10A | |
| SCHEMBL20198855 | 0.84 | PDE10A (0.45) | FFAR1MAPTRAB9APDE10A | |
| SCHEMBL20198853 | 0.84 | PDE10A (0.45) | FFAR1MAPTRAB9APDE10A | |
| SCHEMBL30504107 | 0.82 | KDM4E (0.40) | FFAR1NPC1RAB9APDE10A | |
| SCHEMBL20185097 | 0.82 | KDM4E (0.40) | FFAR1NPC1RAB9APDE10A | |
| SCHEMBL29057348 | 0.82 | KDM4E (0.40) | FFAR1NPC1RAB9APDE10A | |
| SCHEMBL29057350 | 0.82 | KDM4E (0.40) | FFAR1NPC1RAB9APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621276-B1 | 2-ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2017-12-27 | — | — | EP | disclosed |
| US-8785467-B2 | Alkoxy pyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2621276-A2 | 2-ALKOXY PYRIMIDINE PDE10 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130158056-A1 | ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| WO-2012044561-A2 | 2-ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158056-A1 | ALKOXY PYRIMIDINE PDE10 INHIBITORS | PDE10A, PDE11A, PDE12 | FFAR1 2798/4885NPC1 3209/4885MAPT 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.